List view / Grid view
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…
A new study from the University of Michigan Rogel Cancer Center, US has revealed that a cytokine and a fatty acid can work together to trigger ferroptosis. Here, Dr Weiping Zou, the lead researcher from the study, outlines how this process could be used to target cancer cells and enhance immunotherapies.
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
Dr Roger Dmochowski, Professor of Urology and Associate Surgeon in Chief for Vanderbilt University Medical Center, discusses the promise of potential new regenerative for Stress Urinary Incontinence.
Messenger RNA (mRNA) may be the ‘skeleton key’ that unlocks the door to fight latent viral infections that have plagued researchers for generations. Dr Sandeep Basnet, Director, Clinical Development at Moderna Therapeutics explores modern vaccine development and why mRNA is taking centre stage.
Dr John Lewis, CEO of Entos Pharmaceuticals, outlines how an innovative proteolipid platform could enable a new class of DNA-based vaccines in this article.
Protecting against conditions that appear in older generations is increasingly becoming a focus of the medical industry. In this article, Dr Andrea Pfeifer, CEO and Director of AC Immune, discusses the current landscape of vaccine development for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
This ebook includes articles about antibody-based therapies that could protect against cancer by utilising a patient's memory B cells. Also included is a piece on an intranasally-delivered monoclonal antibody treatment to potentially protect against SARS-CoV-2.
Included in this ebook are articles on how to develop more effective CAR T cells by modifying the CAR design and why recent findings about ferroptosis in cancer cells could enhance immunotherapies.
Dr Sheraz Gul reviews the drug approvals from 2021 and highlights the novel modalities of molecules that target KRAS and HIF-2α, which have historically been considered as undruggable.
A collaboration between Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) has been established to source cellular functional assays from the global academic community, with the goal of developing novel screens and identifying targets and therapeutic candidates for unmet medical needs. Here, Dr Denise Barrault, Director of…
Precision medicine in neurology is limited by a dearth of clinically relevant models. However, here Dr Evangelos Kiskinis, Assistant Professor at Northwestern University Feinberg School of Medicine, discusses how new technologies such as bioelectronic assays enable real-time, long-term analysis of neurological diseases in a dish, offering a pathway towards identifying…
In this ebook, you can find articles on the development of novel assays and technology - download now for free!
In this ebook, find articles on vaccination strategies for neurodegenerative diseases and the benefits of mRNA vaccine platforms against latent viruses.
